fb418
Parkinson Disease Psychosis
1ST Biotherapeutics, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Parkinson Disease Psychosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acp-103 Humanis Saglık Anonim Sirketi | Phase 4 | BB |
Ulotaront Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | B |
agb101 Johns Hopkins University | Phase 2 | CCC |
Iloperidone Vanda Pharmaceuticals | Phase 2 | CCC |
ly03017 Luye Pharma Group Ltd. | Phase 1 | CC |
azd0530 King's College London | Early Phase 1 | C |
Same molecule, other indications
fb418 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →